quarterli updat point pipelin catalyst easl
report financi result includ hcv royalti
estim consensu estim guidanc
hcv sale drive estim vs consensu
expect addit rsv studi initi
nash trial initi pbc intrepid data
preclin pk/pd data present
core-inhibitor hbv data support dose detail
addit studi viremic-hbv patient initi
lower pt detail insid
hcv quarterli royalti consensu
estim report hcv sale y/i base
lower volum certain intern market increas compeititon within
us managed-medicaid guid hcv sale drive
vs consensu estim hcv royalti
rsvp adult-outpati studi on-going data
expect vs prior due earlier-than-expect north american
rsv season prompt studi resum southern hemispher fda draft
guidanc inform approach support adopt hcps/payer
addit studi adult pediatr transplant patient remain track
initi
trial biopsy-proven nash on-track
initi studi includ interim analysi
anticip inform dose optim potenti combin plan
oral present result april pbc
intrepid data remain track read-out
follow-on fxr-agonist studi remain track initi
top-line data expect may improv liver gi-
direct distribut increas potenc potenti allow lower dose
reduc pruritu vs fxr suspect ldl-c increas like
circumv plan present preclin pk/pd profil
core-inhibitor hbv sad mad pk data
healthi volunt support dose favor safety/
toler profil detail present initi
evalu antivir efficaci nuc-suppress chronic-hbv patient
data expect addit studi viremic-hbv patient initi
year price histori
chemistry-driven approach drug
discoveri capabl creat small
molecul drug viral infect
hepat viru
respiratori syncyti viru rsv
analyst certif import disclosur see disclosur
assum hcv royalti fund on-going develop
pipelin asset potenti bd
assum hcv stabl
assum develop nash rsv
acceler enter market
estim pbc nash respect
greater expect sale mavyret
hbv rsv drug acceler clinic progress
enta uniqu approach drug develop focus
thorough optim compound could provid competit
advantag nash pbc compani success
demonstr hcv mavyret expect continu
perform mavyret hcv deliv royalti fund
develop new pipelin asset nash pbc hbv
chronic-hbv data
viremic-hbv trial initi
nash trial initi
pbc intrepid data
rsv transplant patient trial initi
rsv rsvp data
fail develop rsv nash pbc
mavyret fail defend market share
price target base dcf valuat methodolog assum wacc residu growth rate
due patent expir model
key downsid risk clinic develop risk regulatori risk current phase trial addit risk come
lower expect peak sale market hcv drug due higher anticip competit failur
gain support medic commun healthcar prescrib third-parti payor
nash
probabl success
risk-adjust nash
rsv
probabl success
risk-adjust rsv
collabor revenu mileston
good
research develop
adjust research develop non-gaap
share-bas compens
total share-bas compens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compens
total share-bas compens exclud non-gaap op ex
interest dividend incom
stock price compani mention report jan
